(Reuters) – Biogen Inc (NASDAQ) announced Tuesday that its Chief Executive Officer Michel Vounatsos would be retiring and it has begun a search to find a replacement.

Company reported a 26% decrease in its quarterly profit due to the continued pressure from cheaper treatments for multiple sclerosis drugs Tecfidera.